These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28095307)

  • 21. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS.
    Uckun FM; Cahn P; Qazi S; D'Cruz O
    Expert Opin Investig Drugs; 2012 Apr; 21(4):489-500. PubMed ID: 22360744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection.
    Kalapila AG; Marrazzo J
    Med Clin North Am; 2016 Jul; 100(4):927-50. PubMed ID: 27235622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers.
    Mukandavire Z; Mitchell KM; Vickerman P
    Epidemics; 2016 Mar; 14():62-70. PubMed ID: 26972515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP.
    Blumenthal J; Jain S; Krakower D; Sun X; Young J; Mayer K; Haubrich R;
    AIDS Behav; 2015 May; 19(5):802-10. PubMed ID: 25616837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV.
    Campbell JD; Herbst JH; Koppenhaver RT; Smith DK
    Am J Prev Med; 2013 Jan; 44(1 Suppl 2):S63-9. PubMed ID: 23253764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antiretroviral drugs-based HIV prevention methods: what impact on the HIV epidemic?].
    Supervie V
    Med Sci (Paris); 2013 Apr; 29(4):373-82. PubMed ID: 23621932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
    van de Vijver DA; Boucher CA
    Curr Opin Infect Dis; 2010 Dec; 23(6):621-7. PubMed ID: 20847692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How many MSM in Europe could benefit from PrEP--a 9 billion Euro question?
    Kenyon CR; Osbak K
    Int J STD AIDS; 2015 Nov; 26(13):988-90. PubMed ID: 26490178
    [No Abstract]   [Full Text] [Related]  

  • 29. Considerations for implementing oral preexposure prophylaxis: a literature review.
    Sowicz TJ; Teitelman AM; Coleman CL; Brawner BM
    J Assoc Nurses AIDS Care; 2014; 25(6):496-507. PubMed ID: 25305026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and characteristics of users of pre-exposure prophylaxis (PrEP) among men who have sex with men, San Francisco, 2014 in a cross-sectional survey: implications for disparities.
    Snowden JM; Chen YH; McFarland W; Raymond HF
    Sex Transm Infect; 2017 Feb; 93(1):52-55. PubMed ID: 27356041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transitioning to HIV Pre-Exposure Prophylaxis (PrEP) from Non-Occupational Post-Exposure Prophylaxis (nPEP) in a Comprehensive HIV Prevention Clinic: A Prospective Cohort Study.
    Siemieniuk RA; Sivachandran N; Murphy P; Sharp A; Walach C; Placido T; Bogoch II
    AIDS Patient Care STDS; 2015 Aug; 29(8):431-6. PubMed ID: 26154174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood safety implications of donors using HIV pre-exposure prophylaxis.
    Seed CR; Yang H; Lee JF
    Vox Sang; 2017 Jul; 112(5):473-476. PubMed ID: 28370177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety data needed for concurrent use of ARV-based PrEP.
    Dunbar MS; Rodrigues J; Chatani M; Baeten JM; Hendrix CW; Palanee-Phillips T; van der Straten A; Mgodi N; Brown E; Makura C; Namwanje S; Torjesen K
    Lancet HIV; 2022 Nov; 9(11):e742-e744. PubMed ID: 36179732
    [No Abstract]   [Full Text] [Related]  

  • 34. [PrEP in French-speaking Switzerland: between anxiety and trust, antiretroviral use for HIV prevention].
    Genre N; Christinet V
    Rev Med Suisse; 2023 Sep; 19(842):1714-1717. PubMed ID: 37728266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV pre-exposure prophylaxis (PrEP)--a quantitative ethics appraisal.
    Kokolo MB; Fergusson DA; Cameron DW
    PLoS One; 2011; 6(8):e22497. PubMed ID: 21850229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telehealth Interventions for HIV in Low- and Middle-Income Countries.
    Phan JM; Kim S; Linh ĐTT; Cosimi LA; Pollack TM
    Curr HIV/AIDS Rep; 2022 Dec; 19(6):600-609. PubMed ID: 36156183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance.
    Supervie V; Barrett M; Kahn JS; Musuka G; Moeti TL; Busang L; Blower S
    Sci Rep; 2011; 1():185. PubMed ID: 22355700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy.
    Youle M; Wainberg MA
    J Int Assoc Physicians AIDS Care (Chic); 2003; 2(3):102-5. PubMed ID: 14556428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translational Models to Predict Target Concentrations for Pre-Exposure Prophylaxis in Women.
    Lantz AM; Nicol MR
    AIDS Res Hum Retroviruses; 2022 Dec; 38(12):909-923. PubMed ID: 36097755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can HIV Infection Be Prevented With Medication?
    Jin J
    JAMA; 2019 Jun; 321(22):2252. PubMed ID: 31184742
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.